POXEL FRANCE Price to Book Ratio 2019-2020 | PXXLF

Historical price to book ratio values for POXEL FRANCE (PXXLF) over the last 10 years. The current price to book ratio for POXEL FRANCE as of October 15, 2021 is 5.26.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

POXEL FRANCE Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
0.00 nan
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.161B $0.008B
Poxel SA is a biopharmaceutical company. It offers drugs for metabolic diseases such as diabetes and related metabolic disorders. The company's product pipeline consists of Imeglimin, PXL770 and PXL007 which are in clinical trial stage. Poxel SA is headquartered in Lyon, France.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00